<DOC>
	<DOCNO>NCT01718145</DOCNO>
	<brief_summary>The purpose study assess anti-viral activity BMS-790052 BMS-650032 combination therapy Japanese subject . The purpose study compare anti-viral activity co-administration Asunaprevir ( ASV ) Daclatasvir ( DCV ) Telaprevir ( TVR ) include therapy Japanese Hepatitis C virus ( HCV ) subject</brief_summary>
	<brief_title>A Phase 3 , Comparative Study Asunaprevir Daclatasvir Combination Therapy Versus Telaprevir Therapy Japanese HCV Subjects</brief_title>
	<detailed_description>Intervention Model : Parallel Naive cohort Single group Relapser cohort</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Chronic HCV1b infect patient HCV Ribonucleic acid ( RNA ) &gt; 100,000 IU/mL screening Ages 20 70 year ( Naive cohort ) , age 20 75 year ( Relapser cohort ) Treatment naive subject Interferon ( IFN ) base therapy Subjects undetectable HCV RNA end treatment prior exposure IFNcontaining regimen , HCV RNA detectable within 24 week treatment followup Patients ; Hepatocellular carcinoma Coinfection Hepatitis B virus ( HBV ) Human immunodeficiency virus ( HIV ) Severe uncontrollable complication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>